Cytologic DNA methylation for managing minimally abnormal cervical cancer screening results.

ABSTRACT:

Objectives

To explore the role of a DNA methylation assay for managing minimally abnormal cervical cancer screening results in a prospective cohort undergoing opportunistic cervical cancer screening.

Methods

In the cohort of the METHY2 and METHY3 screening studies of women undergoing opportunistic cervical cancer screening, cervical cytology samples were sent for high-risk human papillomavirus (hrHPV) DNA assays, cytologic pathology and methylation assays of PAX1/JAM3 (CISCER). This study evaluated the discriminative power of CISCER in managing women with minimally abnormal cervical cancer screening results for CIN3+. Absolute CIN3+ risks and colposcopy referrals within one screening round were calculated.

Results

A total of 1857 women with minimally abnormal cervical

SUBMITTER: Shang X 

PROVIDER: S-EPMC12447664 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature